Biomea Fusion, Inc. to Present Preclinical Data for BMF-650 and Icovamenib at ObesityWeek® 2025

Biomea Fusion will present new data on obesity treatments BMF-650 and icovamenib at ObesityWeek 2025 in Atlanta.

Quiver AI Summary

Biomea Fusion, Inc. announced that it will showcase poster presentations at ObesityWeek® 2025 in Atlanta from November 4-7, focusing on its preclinical data for BMF-650, a next-generation oral GLP-1 receptor agonist, and combination data for its first-in-class menin inhibitor, icovamenib, with semaglutide. The first poster will detail the preclinical efficacy of BMF-650, while the second will discuss how the combination therapy enhances weight loss and preserves lean mass in ZDF rats. Both abstracts will be published in the Obesity journal supplement. Biomea aims to develop innovative treatments for diabetes and obesity, addressing a significant global health issue.

Potential Positives

Biomea Fusion will present significant preclinical data for its next-generation oral small molecule GLP-1 receptor agonist, BMF-650, at a major industry conference (ObesityWeek® 2025), enhancing its visibility and credibility in the metabolic disorder space.
The company is showcasing combination data for its investigational drug icovamenib with semaglutide, potentially highlighting innovative treatment options that could have significant implications for weight management and diabetes care.
All abstracts from the presentations will be published in a peer-reviewed journal, which may bolster the scientific legitimacy and recognition of Biomea's research efforts in the medical community.

Potential Negatives

Limited information is provided about the clinical study results or timelines for the investigational drugs, which may raise concerns about the company's transparency and progress.
The press release does not mention any existing partnerships or collaborations, potentially indicating a lack of industry support or validation for its projects.
Highlighting investigational drugs without established safety or efficacy data may lead to skepticism from investors and healthcare professionals regarding the company's claims.

FAQ

What is Biomea Fusion presenting at ObesityWeek® 2025?

Biomea Fusion is presenting preclinical data for BMF-650 and combination data for icovamenib with semaglutide.

When are the poster presentations scheduled?

The poster presentations will take place on November 4, 2025, from 7:30 p.m. to 8:30 p.m. ET.

What is BMF-650?

BMF-650 is an investigational oral small-molecule GLP-1 receptor agonist designed for obesity treatment.

What is icovamenib's role in diabetes treatment?

Icovamenib is a covalent inhibitor of menin that aims to enhance insulin-producing beta cell function.

How does Biomea Fusion aim to impact diabetes and obesity treatment?

Biomea Fusion focuses on developing transformative oral therapies for diabetes and obesity to improve patient health.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$BMEA Hedge Fund Activity

We have seen 45 institutional investors add shares of $BMEA stock to their portfolio, and 64 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

HEIGHTS CAPITAL MANAGEMENT, INC added 3,839,349 shares (+inf%) to their portfolio in Q2 2025, for an estimated $6,910,828
FMR LLC added 1,808,109 shares (+33.3%) to their portfolio in Q2 2025, for an estimated $3,254,596
WOODLINE PARTNERS LP added 1,502,990 shares (+624.1%) to their portfolio in Q2 2025, for an estimated $2,705,382
BLACKROCK, INC. removed 1,406,440 shares (-65.1%) from their portfolio in Q2 2025, for an estimated $2,531,592
BLUE OWL CAPITAL HOLDINGS LP added 1,300,000 shares (+inf%) to their portfolio in Q2 2025, for an estimated $2,340,000
AISLING CAPITAL MANAGEMENT LP added 1,250,000 shares (+156.5%) to their portfolio in Q2 2025, for an estimated $2,250,000
VANGUARD GROUP INC added 501,626 shares (+36.4%) to their portfolio in Q2 2025, for an estimated $902,926

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$BMEA Analyst Ratings

Wall Street analysts have issued reports on $BMEA in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

D. Boral Capital issued a "Buy" rating on 10/27/2025
Jefferies issued a "Buy" rating on 08/28/2025
Citigroup issued a "Buy" rating on 08/11/2025
Piper Sandler issued a "Overweight" rating on 06/03/2025
HC Wainwright & Co. issued a "Buy" rating on 05/06/2025

To track analyst ratings and price targets for $BMEA, check out Quiver Quantitative's $BMEA forecast page.

$BMEA Price Targets

Multiple analysts have issued price targets for $BMEA recently. We have seen 6 analysts offer price targets for $BMEA in the last 6 months, with a median target of $8.5.

Here are some recent targets:

Jason Kolbert from D. Boral Capital set a target price of $16.0 on 10/27/2025
Roger Song from Jefferies set a target price of $5.0 on 08/28/2025
Yigal Nochomovitz from Citigroup set a target price of $7.0 on 08/11/2025
George Farmer from Scotiabank set a target price of $10.0 on 08/06/2025
Edward Tenthoff from Piper Sandler set a target price of $7.0 on 06/03/2025
Joseph Pantginis from HC Wainwright & Co. set a target price of $18.0 on 05/06/2025

Full Release

SAN CARLOS, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced that it will present poster presentations at ObesityWeek® 2025, taking place November 4-7, 2025 in Atlanta, Georgia.

The presentations will highlight preclinical data for BMF-650, Biomea’s next-generation oral small molecule glucagon-like peptide-1 (“GLP-1”) receptor agonist (“RA”), and combination data for icovamenib, the company’s first-in-class covalent menin inhibitor, with semaglutide, a GLP-1 based therapy.

Presentation details:

Presentation Poster-085
Title: Preclinical Efficacy of BMF-650 An Oral Small Molecule GLP-1 Receptor Agonist
Presentation Date and Time: November 4, 2025 at 7:30 p.m. - 8:30 p.m. ET

Presentation Poster-136
Title: Icovamenib and Semaglutide Combination Enhances Weight Loss While Preserving Lean Mass in ZDF Rats
Presentation Date and Time : November 4, 2025 at 7:30 p.m. - 8:30 p.m. ET

All abstracts will be published in the peer-reviewed Obesity journal supplement. Biomea will provide additional information in accordance with ObesityWeek® abstract embargo policies.

About Icovamenib
Icovamenib is an investigational, orally bioavailable, potent, and selective covalent inhibitor of menin. The proposed mechanism of action for icovamenib in diabetes is selective and partial inhibition of menin, a regulator of beta cell quantity and function, thereby enabling the proliferation, preservation, and reactivation of a patient’s own healthy, functional, insulin-producing beta cells. As the first non-chronic therapy for T2D, icovamenib could become an important addition to the diabetes treatment landscape once it has successfully completed its ongoing clinical studies.

About BMF-650
BMF-650 is an investigational, next-generation oral small-molecule GLP-1 RA being developed by Biomea Fusion for the treatment of obesity. Related to the broader orforglipron chemotype, BMF-650 is designed to combine enhanced oral bioavailability and durable receptor activation to deliver robust metabolic benefits.

About Biomea Fusion
Biomea Fusion is a clinical-stage diabetes and obesity medicines company focused on the development of its oral small molecule therapies, icovamenib and BMF-650, for diabetes and obesity. These programs target metabolic disorders, a global health challenge affecting nearly half of Americans and one-fifth of the world’s population. Biomea’s mission is to deliver transformative treatments that restore health for patients living with diabetes, obesity, and related conditions. We aim to cure.

Visit us at biomeafusion.com and follow us on LinkedIn , X and Facebook .

Contact :
Meichiel Jennifer Weiss
Sr. Director, Investor Relations and Corporate Development
[email protected]